Return on Capital Employed Insights for Wabash National

After pulling data from Benzinga Pro it seems like during Q2, Wabash National (NYSE:WNC) earned $22.68 million, a 102.26% increase from the preceding quarter.

After pulling data from Benzinga Pro it seems like during Q2, Wabash National (NYSE:WNC) earned $22.68 million, a 102.26% increase from the preceding quarter. Wabash National also posted a total of $449.42 million in sales, a 14.65% increase since Q1. In Q1, Wabash National earned $11.21 million, and total sales reached $392.00 million.

Why ROCE Is Significant

Changes in earnings and sales indicate shifts in Wabash National’s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Wabash National posted an ROCE of 0.06%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company’s recent performance, but several factors could affect earnings and sales in the near future.

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Wabash National is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

In Wabash National’s case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Upcoming Earnings Estimate

Wabash National reported Q2 earnings per share at $0.21/share, which beat analyst predictions of $0.12/share.

Total
0
Shares
Related Posts
Read More

Earnings Preview: 10x Genomics

10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement. Analysts estimate that 10x Genomics will likely report an Earnings Per Share (EPS) of $-0.20

TXG